Trials / Completed
CompletedNCT02875132
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pembrolizumab | pembrolizumab at 200mg IV infusion every 3 weeks |
Timeline
- Start date
- 2017-02-15
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2016-08-23
- Last updated
- 2025-04-18
- Results posted
- 2025-04-18
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT02875132. Inclusion in this directory is not an endorsement.